Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive neuromuscular diseases caused by dystrophin gene mutations. Deletions, or more rarely duplications, of single or multiple exons within the dystrophin gene can be detected by current molecular methods in approximately 65% of DMD patients. Mothers of affected males have a two-thirds chance of carrying a dystrophin mutation, whilst approximately one-third of affected males have de novo mutations. Currently, Southern blot analysis and multiplex PCR directed against exons in deletion hot spots are used to determine female carrier status. However, both of these assays depend on dosage assessment to accurately identify carriers since, in females, the normal X chromosome is also present. To obviate quantitation of gene dosage, we have developed exon-specific probes from the dystrophin gene and applied them to a screen for potential carrier females using fluorescence in situ hybridization (FISH). Cosmid clones, representing 16 exons, were identified and used in FISH analysis of DMD/BMD families. Our preliminary work has identified multiple, informative probes for several families with dystrophin deletions and has shown that a FISH-based assay can be an effective and direct method for establishing the DMD/BMD carrier status of females.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder that affects 1/3500 liveborn males. 1 Most affected males appear healthy at birth but may achieve certain developmental milestones (such as walking) at time points later than unaffected children. By five years of age, proximal muscle weakness is apparent and decreased muscle strength causes eventual loss of ambulation by early adolescence. The disease progresses to include distal muscle loss and respiratory and/or cardiac failure and ultimately causes death. 1 Mutations in the dystrophin gene, which maps to Xp21, are responsible for DMD. 2 Dystrophin is an unusually large gene, spanning at least 79 exons. Approximately 60% of mutations in the dystrophin gene, leading to either Duchenne muscular dystrophy or the milder, allelic Becker muscular dystrophy (BMD), are deletions. 3 Frameshift deletions result in DMD (with no functional dystrophin protein produced), while deletions that maintain the reading frame produce the BMD phenotype (partially functional dystrophin present). Within the dystrophin gene, these deletions tend to cluster in hot spots, 3 two of which map towards the 5' end of the gene (encompassing exons 3-7) and the central portion of the gene (encompassing exons 43-51). Approximately two-thirds of mothers of affected males with known deletions are themselves asymptomatic carriers of DMD (about 30% of males with DMD represent de novo mutations). The current methods most commonly used for molecular diagnosis of deletions at the DMD/BMD locus involve exonspecific PCR and Southern analysis to distinguish between deleted and nondeleted individuals. These molecular diagnostic techniques are excellent for detecting dystrophin deletions in males. However, for females, who possess two X chromosomes, the detection of deletions (establishing carrier status) can be problematic, since current methods rely on assessing dosage between regions of the gene. In principle, a carrier female should show half the normal signal intensity by Southern analysis, however this determination can be somewhat subjective and the ability to establish a dosage difference might vary from laboratory to laboratory. While quantitative PCR has been used to address this problem, 4 the issue of subjective interpretation remains. In contrast, FISH analysis for chromosomal deletions is a well-established technique that has been, and continues to be, used to identify a number of deletion symdromes. 5 In limited studies, probes ranging in size from cDNAs to genomic inserts cloned into yeast artificial chromosomes (YACs) have been successfully applied towards detection of DMD deletions. [6] [7] [8] [9] FISH offers a number of advantages, including:
(1) dosage assessment is alleviated, (2) radioisotopes are unnecessary because signal detection is achieved through fluorescence, and (3) direct visual assessment of the presence or absence of a deletion (ie either one or two fluorescent signals present on the homologous chromosome).
Thus, FISH is a qualitative approach, instead of a quantitative-based data interpretation. In the first reported study, FISH analysis was performed to assess DMD patients whose deletions included exon 45 of dystrophin and their female relatives. 6 A set of three cosmid clones spanning the region including exon 45 was used to confirm the carrier status in all individuals tested. This study showed the utility of a fluorescence-based approach for which scoring of the results is relatively rapid and direct. In a more recent study, the feasibility of offering a panel of exonspecific cosmid probes was assessed. 10 
Materials and methods

Isolation of exon-specific cosmids
To obtain probes for screening purposes, primer sets from a dystrophin multiplex PCR assay were used to amplify exons of interest from human genomic DNA as described. 12, 13 Products were obtained for the following exons: 3-6; 8, 12, 13, 17, 19, 43, 44, 45, 48, 50, 51, and 60. The amplified products were gel-purified and the DNA was radiolabeled using the method of random priming (Stratagene Prime-It II Kit, La Jolla, CA, USA.) 14 An X chromosome arrayed cosmid library (LLOXNC01'U') was plated and transferred to a total of 15 nylon membranes and screened sequentially with the appropriate exon-specific PCR-generated probes. Membranes were prehybridized 6 h to overnight in 6X SSC/5X Denhardt's/0.5% SDS/0.5 µg/µl salmon sperm DNA at 65°C. Radiolabeled probes were added at a final concentration of 1-2 ϫ 10 6 cpm/ml and hybridized overnight. Membranes were washed twice for 15 min each in 2X SSC/1% SDS at 65°C and once for 20 min in 1X SSC/0.1% SDS at 65°C. Moist membranes were sealed in plastic wrap, placed next to Kodak XAR film using intensifying screens, and exposed at -80°C for 8 h to 5 days. Positive clones were identified, streaked on LB-kanamycin plates, cultured and DNA extracted following standard protocols.
15
Characterization of cosmids Identified cosmids were characterized to ensure the presence of the target exon as well as the absence of any neighboring exons. With the same primers used previously for PCR, DNA from each cosmid clone was amplified to test for the presence of the desired exon. Cosmids identified to contain the same exon were digested with a series of restriction enzymes to identify differential patterns which may indicate either unique or identical/overlapping clones. Selected clones were then screened by PCR for neighboring exons. When possible, clones containing only a single exon were used for FISH. A single, representative cosmid was chosen for FISH when multiple cosmids were determined to include the same exon.
FISH analysis of DMD families
Blood samples were collected from 24 DMD/BMD families who were interested in participating in the research and development of a new diagnostic tool. Samples were cultured, metaphase chromosomes were obtained, and slides were prepared according to standard cytogenetic protocols. To confirm hybridization of the target probe in males, metaphases from a normal female control pellet were placed to the right-hand side of the affected male sample on the microscope slide. Cosmid probes were labeled with digoxigenin by the method of nick-translation as previously described. 16 An alpha-satellite X chromosome probe was purchased labeled with biotin (Oncor; Gaithersburg, MD or Vysis, Inc., Downers Grove, IL, USA) and 0.5 µl was added to each slide to aid in the identification of the X chromosomes. Figure 1A) . Once a probe(s) was identified as deleted in an affected male, the same probe(s) would be used to screen female relatives in the family. Female carriers show only one signal for the dystrophin cosmid on the normal X chromosome and two centromeric signals (one on each homologue) ( Figure 1B) . In contrast, a non-carrier female would show two cosmid signals and two centromeric signals ( Figure 1C) . In some families, the affected male was not available for analysis. Whenever possible, the FISH probe was demonstrated as deleted in a known carrier, before testing other female relatives.
Patient population
Families with a history of DMD were ascertained through genetic centers and muscular dystrophy clinics in the United Figure 1 Representative FISH results for three families. A FISH using cosmid 36E6, containing exons 3-6, on the affected DMD male from Family 1 showed only the green centromeric signal (arrow) and absence of the cosmid signal, demonstrating a deletion on his X chromosome. B FISH using cosmid 138E6, containing exon 12, on the daughter of a BMD male in Family 13 showed a deletion of the cosmid signal on one X chromosome (arrow), demonstrating that she is a carrier. C FISH using cosmid 141G11, containing exon 44, on the sister in Family 6 showed a normal hybridization pattern to both X chromosomes (arrows), indicating that she is not a carrier of the DMD deletion.
States. Thirty-six individuals, from 24 families, were studied using FISH. Of these, eight families had affected males with known molecular deletions available for study. Of the remaining 16 families, for whom affected males were not available, prior molecular results were available for 17 of 19 females studied using FISH.
Results
The screening of the X chromosome specific cosmid library identified 13 dystrophin exon-specific probes (Table 1) . For the eight males tested using FISH, the expected deletion was demonstrated in every case ( Table 2 ). None of the nine corresponding female relatives demonstrated a deletion by FISH. Thus, there was 100% concordance with the available molecular diagnostic results (5/9 females tested by standard molecular methods). Of the 19 females studied using FISH for whom no affected male was available, prior molecular results were available for 17 cases. For these, deletions were found using FISH in seven, demonstrating complete agreement with the prior molecular results. For two mothers, molecular analysis for carrier detection had not been performed and no deletions were detected using FISH. Therefore, for these women, it is uncertain if the probes used fall within the deleted region and these women are truly not carriers or, 50  deleted  affected  mother  female  none  50  normal  noncarrier  5  proband  male  7-13  8  deleted  affected  sister  female  not tested  8  normal  noncarrier  sister  female  not tested  8  normal  noncarrier  6  proband  male  44  44  deleted  affected  sister  female  none  44  normal  noncarrier  7  proband  male  45-50  48  deleted  affected  mother  female  not tested  48  normal  noncarrier  8  proband  male  50-52  51  deleted  affected  mother  female  not tested  51  normal  noncarrier  9  mother  female  46-48  48  deleted  carrier  sister  female  none  48  normal  noncarrier  10  mother  female  49-50  50  deleted  carrier  sister  female  none  50  normal  noncarrier  11  sister  female 
Discussion
Since the dystrophin gene is so large, it presents unique advantages and disadvantages in a diagnostic setting. To develop a FISH-based approach, the 79 exons in this gene suggest that many exon-specific cosmids must be obtained so that the majority of families with deletions for any exon can be identified. However, dystrophin deletions are known to cluster in hot spots. 3, 11 Rosenberg et al 11 developed a set of FISH probes based on these hot spot regions. We have also identified cosmids for each of these hot spot regions, enabling carrier status to be elucidated for a large majority of mothers and female relatives of boys with deletions in the dystrophin locus. Additionally, we developed probes outside the deletion hot spots that have allowed for deletion identification in a larger number of families (families 5, 13, 15, and 19). Family 19, and possibly families 9 and 23, would not have been identified using the probe set developed by Rosenberg et al.
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Probes were validated through comparison with molecular results obtained using established and accepted methods of diagnostic testing. In every case, our molecular cytogenetic data were in complete agreement with the known molecular data (n = 30 individuals). By analyzing potential carrier females in a blinded fashion (ie with no knowledge of molecular testing results prior to scoring of the FISH results), the sensitivity of the assay (ie the probability that a true deletion is scored as such) could be determined and was found to be 100% in this investigation. In addition, each known non-deleted case was confirmed by the FISH assay, thus providing a specificity of 100% in our samples. Both these parameters provide a measure of the robustness of this FISH-based approach.
Our results confirm those obtained from a recent pilot study performed by our laboratory 10 and those reported previously describing the use of FISH analysis for DMD. [6] [7] [8] [9] 11 In each case, the carrier status (or disease status) could be correctly identified using FISH. However, there are some restrictions to the use of a FISH-based approach to carrier testing. First, most DMD patients that have dystrophin gene deletions (about 60%) or intragenic duplications (about 5%) can be tested using FISH; those with point mutations will have to rely on molecular analysis or linkage assessment to establish carrier status. Second, it is expected that certain deletions will be smaller in size than the probe used for testing. In these instances, a particular exon may be deleted but surrounding intronic sequences may not, so a deleted individual may show a normal hybridization pattern and be scored as not deleted (normal). Third, not all patients with deletion of the same exons will have the identical deletion endpoints. Since this variability will undoubtedly exist between families, a probe that is informative within a given family may not be informative for others. It is precisely for this reason that all probes to be used in a family must first be shown to be deleted in an individual who has had a deletion identified through prior molecular testing (affected males or carrier females). It would be inappropriate to suggest that FISH be used in place of either multiplex PCR or Southern analysis to confirm or make a diagnosis of DMD/BMD in an affected male, or in a family in which no individual has had a prior molecular analysis. It is not possible to date, nor feasible with current FISH technologies, to analyze all dystrophin exons using FISH. Instead, we have demonstrated that FISH is an attractive, alternative approach to screen female relatives of a known affected male with a molecular diagnosis of DMD or BMD. The ultimate goal of this work is to isolate probes representing all, or at least the majority, of the exons in the dystrophin gene so that FISH analysis can be performed for the majority of DMD families who carry deletions. These probes may be amenable to new FISH technologies, such as simultaneous detection devices 17 and micro-array technologies 18 to allow for rapid and accurate assessment for deletions in males and females.
